A Study of MK1775 in Combination With Topotecan/Cisplatin in Patients With Cervical Cancer (1775-008)

Inclusion Criteria:

• Patient has advanced, metastatic, and recurrent squamous cell, adenosquamous, or adeno-carcinoma of the uterine cervix (Stage II - IVb)
• Patient has received cisplatin in combination with radiation as initial or adjuvant treatment for their cervical cancer
• Patient has not received any other treatment for their cancer following the cisplatin-based chemo-radiation or targeted therapy except non-cytotoxic targeted therapy
• Recurrence must be at least 6 months post cisplatin-based chemotherapy
• Patient has measurable disease
• Patient's performance status on the Eastern Cooperative Oncology Group (ECOG) Performance Scale is less than or equal to 1
• Patient has a negative pregnancy test within 72 hours of the first dose of study medication

Exclusion Criteria:

• Patient has had chemotherapy, radiotherapy, or biological therapy within 6 months of entering the study
• Patient has a history of vascular thrombotic events or vascular reconstruction
• Patient has active central nervous system (CNS) metastases and/or carcinomatous meningitis
• Patient has a primary CNS tumor
• Patient requires the use of medications or products that are metabolized by, or inhibit or induce CYP3A4 (Cytochrome P450 3A4)
• Patient is expecting to reproduce within the duration of the study or is pregnant or breastfeeding
• Patient is known to be Human Immunodeficiency Virus (HIV)-positive
• Patient has known active Hepatitis B or C
• Patient has a known history of interstitial lung disease or pulmonary fibrosis
• Patient has symptomatic ascites or pleural effusion
• Patient has a clinical history suggestive of Li-Fraumeni Syndrome